Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Formoterol/fluticasone propionate - Mundipharma International/Vectura

Drug Profile

Formoterol/fluticasone propionate - Mundipharma International/Vectura

Alternative Names: Abriff; Fluticasone propionate/formoterol fumarate; Fluticasone/formoterol; Flutiform; flutiform K-Haler; Flutiformo; Flutiform™ HFA-MDI; Formoterol fumarate/fluticasone propionate; FP/FORM - Vectura; Iffeza; KRP-108

Latest Information Update: 23 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SkyePharma PLC
  • Developer Kyorin Pharmaceutical; Mundipharma International; Mundipharma Research; SkyePharma PLC; Vectura
  • Class Antiallergics; Antiasthmatics; Ethanolamines; Glucocorticoids; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • Phase III Chronic obstructive pulmonary disease

Most Recent Events

  • 11 Oct 2019 Mundipharma International plans a phase III trial for Asthama (Treatment-experienced) in South Korea (Inhalation, Aerosol) in December 2019 (NCT04124510)
  • 08 Nov 2018 Formoterol/fluticasone propionate receives positive opinion for Asthma (In children) in Europe
  • 29 Oct 2018 Mundipharma Pharmaceuticals initiates enrolment in a phase I pharmacokinetic trial in healthy volunteers in China (ChiCTR1800019111)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top